Successful discontinuation of secondary prophylaxis for histoplasmosis after higly active antiretroviral therapy

Journal of the Formosan Medical Association

Volumn 103, Issue 7, 2004, Pages 546-548

  Sun, Hsin Yun ^a   Chen, Mao Yuan ^a   Hsieh, Szu Min ^a   Hung, Chien Ching ^a,b   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

AIDS; Antibiotic prophylaxis; Histoplasma; Histoplasmosis

Indexed keywords

AMPHOTERICIN B; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; DERMATOMYCOSIS; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ILEOSTOMY; INFECTION PREVENTION; INTESTINE OBSTRUCTION; LUNG MYCOSIS; MAINTENANCE THERAPY; MALE; MESENTERY; RELAPSE; RETROPERITONEUM; SECONDARY PREVENTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HISTOPLASMOSIS; HUMANS; ITRACONAZOLE; MALE;

EID: 6344235696     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al: Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine 1990;69:361-74.
2. Wheat LJ, Sarosi G, McKinsey D, et al: Practice guidelines for the management of patients with histoplasmosis: Clin Infect Dis 2000;30:688-95.
3. Hung CC, Wong JM, Hsueh PR, et al: Intestinal obstruction and peritonitis resulting from gastrointestinal histoplasmosis in an AIDS patient: J Formos Med Assoc 1998;97:577-80.
4. Bernaldo L, de Quiros JC, Miro JM, et al: A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 44:159-67.
5. Guex AC, Radziwill AJ, Bucher HC: Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000;30:602-3.
6. Shafran SD, Laura D, Phillips P, et al: Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Ann Intern Med 2002;137:734-7.
7. Macdonald JC, Torriani FK, Morse LS, et al: Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998;177:1182-7.
8. Martinez E, Garcia- Viejo MA, Marcos MA, et al: Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000;14:2615-7.
9. Kirk O, Reiss P, Uberti-Foppa C, et al: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002;137:239-50.
10. Sheng WH, Hung CC, Chen MY, et al: Successful discontinuation of fluconazole as secondary prophylaxis for disseminated cryptococcal infections in AIDS patients responding to highly active antiretroviral therapy. Int J STD AIDS 2002;13:702-5.
11. Hung CC, Chen MY, Hsieh SM, et al: Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002; 16:672-3.